Beyond Celiac Expands its Board in Effort to Find a Cure
Todd Hammer and Lisa Agdern Contribute Enhanced Foundation and Investment Management Expertise.
FREMONT, CA: Beyond Celiac, the leading catalyst for a celiac disease cure in the United States, elects Lisa Agdern, executive director, Seidenberg Family Foundation, Inc, and Todd Hammer, co-founder, partner, and co-portfolio manager, North Run Capital, to the organization's Board of Directors.
With the inclusion of Agdern and Hammer, the governing board now has a total of 15 members. Beyond Celiac's Board of Directors guides the organization toward its objective of speeding the development of a cure for celiac disease by 2030.
Agdern, a Pleasantville, New York resident, has two children who have celiac disease. She possesses extensive experience working with foundations and not-for-profit organizations. She graduated from Tufts University with a Bachelor of Arts and Stanford University with a Master of Arts. She is an avid runner who has completed two marathons, most recently the 2016 New York City Marathon, where she collected funds for celiac disease.
Hammer has vast experience conducting business analyses and managing investments. He earned dual degrees from the University of Pennsylvania “a B.S. from the Wharton School and a B.A. from the College of Arts and Sciences “summa cum laude. Additionally, he got a J.D. with honors from Harvard Law School. He is an avid golfer and serial marathon runner who resides in Newton, Massachusetts.
“More than three million Americans live with celiac disease, and under the direction of the Board and the implementation of the strategic science plan, an effective treatment or cure could be possible by 2030,” says Beyond Celiac CEO Alice Bast. “We are pleased that Lisa Agdern and Todd Hammer are taking on this leadership role as we work to accomplish that goal.”
Celiac disease is a severe inherited autoimmune illness that affects approximately one in every 133 Americans, with more than half remaining untreated. The condition damages the small intestine, causing debilitating symptoms and, if left untreated, serious long-term health consequences such as infertility and certain types of cancer.
By Leni Kaufman, VP & CIO, Newport News Shipbuilding
By George Evans, CIO, Singing River Health System
By John Kamin, EVP and CIO, Old National Bancorp
By Elliot Garbus, VP-IoT Solutions Group & GM-Automotive...
By Gregory Morrison, SVP & CIO, Cox Enterprises
By Alberto Ruocco, CIO, American Electric Power
By Sam Lamonica, CIO & VP Information Systems, Rosendin...
By Sergey Cherkasov, CIO, PhosAgro
By Pascal Becotte, MD-Global Supply Chain Practice for the...
By Stephen Caulfield, Executive Director, Global Field...
By Shamim Mohammad, SVP & CIO, CarMax
By Ronald Seymore, Managing Director, Enterprise Performance...
By Brad Bodell, SVP and CIO, CNO Financial Group, Inc.
By Jim Whitehurst, CEO, Red Hat
By Clark Golestani, EVP and CIO, Merck
By Scott Craig, Vice President of Product Marketing, Lexmark...
By Dave Kipe, SVP, Global Operations, Scholastic Inc.
By Meerah Rajavel, CIO, Forcepoint
By Amit Bahree, Executive, Global Technology and Innovation,...
By Greg Tacchetti, CIO, State Auto Insurance